Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22509833 | 0.80 | CYP11B1 (0.45) | NR3C2MMP12CYP11B1CYP11B2PARP1 | |
| SCHEMBL22509843 | 0.76 | MMP12 (0.54) | NR3C2MMP12PARP1ALDH1A1MAPT | |
| SCHEMBL21089783 | 0.76 | KCNH2 (0.40) | NR3C2MMP12CYP11B1CYP11B2PARP1 | |
| SCHEMBL22509751 | 0.76 | NR3C2 (0.39) | NR3C2MMP12CYP11B1CYP11B2PARP1 | |
| SCHEMBL21053191 | 0.75 | PDE3B (0.42) | — | |
| SCHEMBL21054030 | 0.75 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL21055860 | 0.74 | GRM5 (0.41) | ALDH1A1MAPT | |
| SCHEMBL21053947 | 0.74 | BRD4 (0.38) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21054112 | 0.73 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL22521575 | 0.73 | NR3C2 (0.40) | NR3C2MMP12CYP11B1CYP11B2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | NR3C2 4083/4885MMP12 2829/4885CYP11B1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.